Management of patients eligible for CAR-T cell therapy
Evaluation of the Real-life Management of Patients Eligible for CAR-T Cell Therapy for Hematologic Malignancies at Toulouse University Hospital
University Hospital, Toulouse · NCT06369389
This study looks at how patients eligible for CAR-T cell therapy are managed in real life to better understand their needs and care over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 550 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse (other) |
| Drugs / interventions | CAR-T, immunotherapy |
| Locations | 1 site (Toulouse, CHU de Toulouse) |
| Trial ID | NCT06369389 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the real-life management of patients eligible for CAR-T cell therapy for hemopathy at Toulouse University Hospital. It aims to collect data over a five-year period to evaluate patient-centered indicators and care pathways, addressing the growing needs associated with the increasing number of CAR-T cell indications. The study is part of the French national DESCAR-T registry, which serves as a reference for evaluating the post-authorization use of CAR-T treatments.
Who should consider this trial
Good fit: Ideal candidates are patients eligible for CAR-T treatment for hemopathy at Toulouse University Hospital between 2019 and 2028.
Not a fit: Patients who are under guardianship or object to data collection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of CAR-T cell therapy's effectiveness and improve patient care pathways.
How similar studies have performed: Other studies have shown success in evaluating CAR-T therapies, but this specific approach to real-life data collection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient eligible for CAR-T treatment for hemopathy at TOULOUSE University Hospital under early access or marketing authorization or as part of a clinical trial between 01/01/2019 and 31/12/2028 * Patient able to understand the purpose and constraints of the research project * Patient has read the study information leaflet and does not object to the research. Exclusion Criteria: * Patient under guardianship, curatorship or safeguard of justice * Patient objects to the collection of data concerning him/her
Where this trial is running
Toulouse, CHU de Toulouse
- CHU de Toulouse — Toulouse, CHU de Toulouse, France (RECRUITING)
Study contacts
- Principal investigator: Pierre BORIES, MD — University Hospital, Toulouse
- Study coordinator: Pierre BORIES, MD
- Email: bories.pierre@iuct-oncopole.fr
- Phone: 0531156415
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hemopathy, CAR-T cells, real life, care pathways, quality of life